Drug Pipeline

Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.

Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.

Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.

Patient risk can improve value-based cancer care. Find out how.

How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.

The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.

Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.

Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.

Here are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.

A West survey finds that an overwhelming number of chronic care patients say they need help managing their disease.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

Find out about the latest treatment and drug pipeline developments

MCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country.

Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?

A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.

Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.

As the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.

Two reports highlight areas of elderly care that healthcare systems and health plans should avoid.

HHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.

Several recent studies explore how weight loss surgery impacts diabetes patient care.

We recently asked experts to define the top challenges associated with diabetes health management, and how health plans can overcome them.

How much does diabetes cost the healthcare system and what's driving cost increases? Find out.

Here’s how remote monitoring works to improve diabetic patient care, and a look at whether payers are paying for it.

De-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?

Most patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.

Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?

Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.

Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development-and even routine clinical cancer care.

A look at how burnout affects providers, their patients, and the centers that employ them.